Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate
Abstract
Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against SARS-CoV-2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. Comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC50 = 0.0022{micro}M).
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
- Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2
M. Dittmar, J. S. Lee, … S. Cherry·bioRxiv·Jun 19, 2020
- Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo
S. Weston, C. M. Coleman, … M. Frieman·bioRxiv·Mar 25, 2020
- Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2
S. B. Biering, E. Van Dis, … S. A. Stanley·bioRxiv·Dec 30, 2020
- Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells
A. Pickard, B. C. Calverley, … K. E. Kadler·bioRxiv·Jan 31, 2021
- Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19
C. Mirabelli, J. W. Wotring, … J. Z. Sexton·Proceedings of the National Academy of SciencesPeer-reviewed·Aug 19, 2021